Post by
Torontonine on May 07, 2020 2:27pm
No new news
How is LBL any different than VXL or any of the other small cap bio stocks. I'll tell you how . They have the goods and are learning the expertise of how to get a trial going. This literally fell in to their laps. VXL RVV and many other companies are still trying to develope a vaccine. LBL is the complete opposite they have the treatment ,but having a hard time manoeuvring it and getting to market The end game here is either pay big $ to get the trial going or partner up. They would burn the $ 6 Mil b4 going bankrupt and from my conversations with Guy they don't need to use that money. It's a line of credit. Dump if you want, hold if you want , but if this baby pops it will go fast.
Comment by
Accept2 on May 07, 2020 2:35pm
It could also be taken over by another company. Thats my biggest fear here. I bought LBL, not some Yank Von Blickenblocker pharma corp shares that would be exchanged for..........
Comment by
Torontonine on May 07, 2020 2:39pm
Very true but they do have a viable business. The segment is only growing and finally being accepted and a $6 mil life line to boot. Why work for someone else when you can keep operating as an independent.
Comment by
Accept2 on May 07, 2020 5:59pm
Keep the shares in Canada eh?..... https://www.youtube.com/watch?v=8Jm4LoOaAWI
Comment by
Nomoreshells4me on May 07, 2020 10:30pm
https://www.businesswire.com/news/home/20200507005685/en/COVID-19-Stem-Cell-Therapies-Pipeline-2020-Report